+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rhinovirus Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Rhinovirus

  • ID: 4629639
  • Report
  • 65 pages
  • VPA Research
UP TO OFF
until May 30th 2019
1 of 4

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • ARMS Pharmaceutical LLC
  • AstraZeneca Plc
  • Biological Mimetics Inc
  • Haplogen GmbH
  • Meissa Vaccines Inc
  • MORE
Rhinovirus Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Rhinovirus Infection pipeline products.

Report Description

The Rhinovirus Infection pipeline guide presents complete overview of drugs currently being developed for Rhinovirus Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Rhinovirus Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Rhinovirus Infection pipeline candidates is included.

Major companies participating in therapeutic development of Rhinovirus Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Rhinovirus Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Rhinovirus Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Rhinovirus Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Rhinovirus Infection pipeline report includes
  • Panorama of Rhinovirus Infection pipeline markets including statistics on therapeutic drugs and companies involved
  • Rhinovirus Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
  • Rhinovirus Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Rhinovirus Infection pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Rhinovirus Infection pipeline therapeutics
Reasons to Buy
  • Get clear understanding of the entire Rhinovirus Infection pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Rhinovirus Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • ARMS Pharmaceutical LLC
  • AstraZeneca Plc
  • Biological Mimetics Inc
  • Haplogen GmbH
  • Meissa Vaccines Inc
  • MORE
I. Key Findings

1. Companies Investing in Rhinovirus Infection Pipeline include-
Number of Companies with Rhinovirus Infection projects in pre-clinical Development-
Number of Companies with Rhinovirus Infection projects in Clinical Development-
Rhinovirus Infection Pipeline Companies based in Americas
Rhinovirus Infection Pipeline Companies based in Europe
Rhinovirus Infection Pipeline Companies based in Asia Pacific
Rhinovirus Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include-
Rhinovirus Infection Pipeline Agents in pre- clinical/ Discovery stage of Development
Rhinovirus Infection Pipeline Agents in Clinical Development stage
Rhinovirus Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Rhinovirus Infection Pipeline agents

II. Insights into Rhinovirus Infection Pipeline -

1. Disease Overview
Introduction to Rhinovirus Infection
Symptoms and Causes of Rhinovirus Infection
Treatment or Prevention Options for Rhinovirus Infection
Other Details
2. Phase wise Pipeline Compounds
Rhinovirus Infection Pipeline- Pre- Clinical/ Discovery stage Drugs
Rhinovirus Infection Pipeline- Phase 1 stage Drugs
Rhinovirus Infection Pipeline- Phase 2 stage Drugs
Rhinovirus Infection Pipeline- Phase 3 stage Drugs
Rhinovirus Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Rhinovirus Infection Pipeline Compounds
4. Rhinovirus Infection Pipeline by Mechanism of Action

III. Rhinovirus Infection Pipeline Compound Details
  • TVB-3567
  • ARMS-I
  • HRV 3C protease Inhibitor
  • rhinovirus vaccine
  • drug for Rhinovirus Infections
  • polyvalent rhinovirus vaccine
  • PrEP-001
  • HRV Vaccine
  • antiviral therapeutics
  • VVX003
  • Monoclonal Antibodies for Rhinovirus Infections
Drug Details

1. Snapshot-
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Rhinovirus Infection Pipeline Company Briefs
  • 3-V Biosciences Inc
  • ARMS Pharmaceutical LLC
  • AstraZeneca Plc
  • Biological Mimetics Inc
  • Haplogen GmbH
  • Meissa Vaccines Inc
  • PrEP Biopharm Ltd
  • Prokarium Ltd
  • Secarna Pharmaceuticals GmbH&Co.KG
  • Viravaxx AG
  • Zebra Biologics Inc
V. Latest News and Developments in Global Rhinovirus Infection Pipeline Market

VI. Appendix
1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability"
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 3-V Biosciences Inc
  • ARMS Pharmaceutical LLC
  • AstraZeneca Plc
  • Biological Mimetics Inc
  • Haplogen GmbH
  • Meissa Vaccines Inc
  • PrEP Biopharm Ltd
  • Prokarium Ltd
  • Secarna Pharmaceuticals GmbH&Co.KG
  • Viravaxx AG
  • Zebra Biologics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4629639
Adroll
adroll